Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Criteria for treatment with somatostatin analogs (SSAs) of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are presence of somatostatin receptors, a positive Octreoscan® or hormonal decrement >50% after octreotide s.c. injection (octreotide test, OT). We demonstrated that a plasma CgA decrement >/=30% after OT is a selection criterion able to predict the clinical response to SSAs.
Conference:
Presenting Author:
Authors: Rossi R, Massironi S, Spampatti M, Conte D, Ciafardini C,
Keywords: octreotide test, somatostatin analogs,
Introduction: We recently demonstrated that a plasma CgA decrement >30% after octreotide s.c. injection is a simple criterion for treatment with Somatostatin analogues (SSA) of gastroenteropancreatic endocrine tumors.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Massironi S, Spampatti M, Rossi R, Conte D, Ciafardini C,
Keywords: gastroenteropancreatic neuroendocrine tumors (GEP-NETs), octreotide test (OT), prognosis ,
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.
Conference: 7th Annual ENETSConcerence (2010)
Presenting Author: Massironi S
Authors: Massironi S, Conte D, Sciola V, Spampatti M, Rossi R,
Keywords: gastroenteropancreatic neuroendocrine tumors, carcinoids, pancreatic endocrine tumors, chromogranin A, somatostatin analogues,